JP2007502804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502804A5 JP2007502804A5 JP2006523677A JP2006523677A JP2007502804A5 JP 2007502804 A5 JP2007502804 A5 JP 2007502804A5 JP 2006523677 A JP2006523677 A JP 2006523677A JP 2006523677 A JP2006523677 A JP 2006523677A JP 2007502804 A5 JP2007502804 A5 JP 2007502804A5
- Authority
- JP
- Japan
- Prior art keywords
- indole
- methyl
- acetic acid
- phenoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- AMNJIGMMUQRKOL-UHFFFAOYSA-N 2-[2,5-dimethyl-3-(4-methylsulfonylphenoxy)indol-1-yl]acetic acid Chemical compound C12=CC(C)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(S(C)(=O)=O)C=C1 AMNJIGMMUQRKOL-UHFFFAOYSA-N 0.000 claims 1
- GQRFQYQBVWRBOC-UHFFFAOYSA-N 2-[2-methyl-3-(4-methylsulfonylphenoxy)-5-(trifluoromethyl)indol-1-yl]acetic acid Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(S(C)(=O)=O)C=C1 GQRFQYQBVWRBOC-UHFFFAOYSA-N 0.000 claims 1
- NWUQJWTVYYUAAJ-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-2-methyl-4-(propan-2-ylsulfonylamino)indol-1-yl]acetic acid Chemical compound C1=2C(NS(=O)(=O)C(C)C)=CC=CC=2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 NWUQJWTVYYUAAJ-UHFFFAOYSA-N 0.000 claims 1
- SFUPNPSDGVIYIT-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-2-methyl-4-pyrazin-2-ylindol-1-yl]acetic acid Chemical compound C12=C(C=3N=CC=NC=3)C=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 SFUPNPSDGVIYIT-UHFFFAOYSA-N 0.000 claims 1
- MOMVCWJBFVNKBI-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-2-methyl-5-(trifluoromethyl)indol-1-yl]acetic acid Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 MOMVCWJBFVNKBI-UHFFFAOYSA-N 0.000 claims 1
- JFDVCWFRJKHBAG-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-2-methyl-5-methylsulfonylindol-1-yl]acetic acid Chemical compound C12=CC(S(C)(=O)=O)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 JFDVCWFRJKHBAG-UHFFFAOYSA-N 0.000 claims 1
- XFTAGJLXIIDEIQ-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-4-(dimethylsulfamoylamino)-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NS(=O)(=O)N(C)C)=CC=CC=2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 XFTAGJLXIIDEIQ-UHFFFAOYSA-N 0.000 claims 1
- CMGUAOOJGFBGME-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-4-(ethylsulfonylamino)-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NS(=O)(=O)CC)=CC=CC=2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 CMGUAOOJGFBGME-UHFFFAOYSA-N 0.000 claims 1
- YYXNJDGFOGUERM-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-4-(methanesulfonamido)-2-methylindol-1-yl]acetic acid Chemical compound C12=C(NS(C)(=O)=O)C=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 YYXNJDGFOGUERM-UHFFFAOYSA-N 0.000 claims 1
- DUVMLXJCMMEJBQ-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-5-(ethylsulfonylamino)-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(NS(=O)(=O)CC)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 DUVMLXJCMMEJBQ-UHFFFAOYSA-N 0.000 claims 1
- XTXGTLNSIXIKNG-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-5-(methanesulfonamido)-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(NS(C)(=O)=O)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 XTXGTLNSIXIKNG-UHFFFAOYSA-N 0.000 claims 1
- VHTADBIQRDFSEO-UHFFFAOYSA-N 2-[3-(4-chlorophenoxy)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 VHTADBIQRDFSEO-UHFFFAOYSA-N 0.000 claims 1
- XFMGOBWEKPIIEZ-UHFFFAOYSA-N 2-[3-(4-cyanophenoxy)-2-methyl-5-(trifluoromethyl)indol-1-yl]acetic acid Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(C#N)C=C1 XFMGOBWEKPIIEZ-UHFFFAOYSA-N 0.000 claims 1
- LPWWVNDAGZXRJB-UHFFFAOYSA-N 2-[3-(4-cyanophenoxy)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(C#N)C=C1 LPWWVNDAGZXRJB-UHFFFAOYSA-N 0.000 claims 1
- QWEDSNMFNSHPJW-UHFFFAOYSA-N 2-[3-(4-ethylsulfonylphenoxy)-2-methyl-5-(trifluoromethyl)indol-1-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(C(F)(F)F)C=C12 QWEDSNMFNSHPJW-UHFFFAOYSA-N 0.000 claims 1
- PEWWUPWEOHLXHO-UHFFFAOYSA-N 2-[3-(4-ethylsulfonylphenoxy)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 PEWWUPWEOHLXHO-UHFFFAOYSA-N 0.000 claims 1
- DBOLBTFGTCAKQL-UHFFFAOYSA-N 2-[3-[4-(2-aminoethylcarbamoyl)phenoxy]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(C(=O)NCCN)C=C1 DBOLBTFGTCAKQL-UHFFFAOYSA-N 0.000 claims 1
- DNYBPUDMWWJUCW-UHFFFAOYSA-N 2-[3-[4-(dimethylsulfamoyl)phenoxy]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 DNYBPUDMWWJUCW-UHFFFAOYSA-N 0.000 claims 1
- RVPWZGPSADICIM-UHFFFAOYSA-N 2-[3-[4-(ethylcarbamoyl)phenoxy]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(C(=O)NCC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 RVPWZGPSADICIM-UHFFFAOYSA-N 0.000 claims 1
- KVULPJIQOUYTAM-UHFFFAOYSA-N 2-[4-acetamido-3-(4-chlorophenoxy)-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1OC1=CC=C(Cl)C=C1 KVULPJIQOUYTAM-UHFFFAOYSA-N 0.000 claims 1
- USPBPSZVNVSASZ-UHFFFAOYSA-N 2-[5-chloro-2-methyl-3-[4-(methylcarbamoyl)phenoxy]indol-1-yl]acetic acid Chemical compound C1=CC(C(=O)NC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(Cl)C=C12 USPBPSZVNVSASZ-UHFFFAOYSA-N 0.000 claims 1
- FUVTXEXQSCGWMI-UHFFFAOYSA-N 2-[5-chloro-3-(4-methoxycarbonylphenoxy)-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(C(=O)OC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(Cl)C=C12 FUVTXEXQSCGWMI-UHFFFAOYSA-N 0.000 claims 1
- XVOAUDOQFYVQPH-UHFFFAOYSA-N 2-[5-chloro-3-[4-(ethylcarbamoyl)phenoxy]-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(C(=O)NCC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(Cl)C=C12 XVOAUDOQFYVQPH-UHFFFAOYSA-N 0.000 claims 1
- KOLQHEXKKSYHIH-UHFFFAOYSA-N 2-[5-cyano-2-methyl-3-(4-methylsulfonylphenoxy)indol-1-yl]acetic acid Chemical compound C12=CC(C#N)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(S(C)(=O)=O)C=C1 KOLQHEXKKSYHIH-UHFFFAOYSA-N 0.000 claims 1
- NLBZRKXSZWWBEU-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(4-methylsulfonylphenoxy)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(S(C)(=O)=O)C=C1 NLBZRKXSZWWBEU-UHFFFAOYSA-N 0.000 claims 1
- GOVOMGOBTOATIQ-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-[4-(methylcarbamoyl)phenoxy]indol-1-yl]acetic acid Chemical compound C1=CC(C(=O)NC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 GOVOMGOBTOATIQ-UHFFFAOYSA-N 0.000 claims 1
- DFJVMPUTMSLQDA-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-[4-(propan-2-ylcarbamoyl)phenoxy]indol-1-yl]acetic acid Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 DFJVMPUTMSLQDA-UHFFFAOYSA-N 0.000 claims 1
- YKZVMXZHFUBANW-UHFFFAOYSA-N 2-[5-fluoro-3-(4-methoxycarbonylphenoxy)-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(C(=O)OC)=CC=C1OC1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 YKZVMXZHFUBANW-UHFFFAOYSA-N 0.000 claims 1
- JZRIZGDEYMWJKQ-UHFFFAOYSA-N 4-[1-(carboxymethyl)-5-chloro-2-methylindol-3-yl]oxybenzoic acid Chemical compound C12=CC(Cl)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(C(O)=O)C=C1 JZRIZGDEYMWJKQ-UHFFFAOYSA-N 0.000 claims 1
- YVXQADDGUVCRDQ-UHFFFAOYSA-N 4-[1-(carboxymethyl)-5-fluoro-2-methylindol-3-yl]oxybenzoic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1OC1=CC=C(C(O)=O)C=C1 YVXQADDGUVCRDQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302232-4 | 2003-08-18 | ||
| SE0302232A SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Novel Compounds |
| PCT/GB2004/003502 WO2005019171A1 (en) | 2003-08-18 | 2004-08-16 | Substituted indole derivatives for pharmaceutical composition for treating respiratory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007502804A JP2007502804A (ja) | 2007-02-15 |
| JP2007502804A5 true JP2007502804A5 (enExample) | 2007-09-27 |
| JP4709758B2 JP4709758B2 (ja) | 2011-06-22 |
Family
ID=28450248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523677A Expired - Fee Related JP4709758B2 (ja) | 2003-08-18 | 2004-08-16 | 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7709521B2 (enExample) |
| EP (1) | EP1656347B1 (enExample) |
| JP (1) | JP4709758B2 (enExample) |
| AR (1) | AR045462A1 (enExample) |
| AT (1) | ATE484494T1 (enExample) |
| CY (1) | CY1110977T1 (enExample) |
| DE (1) | DE602004029580D1 (enExample) |
| DK (1) | DK1656347T3 (enExample) |
| ES (1) | ES2352201T3 (enExample) |
| MY (1) | MY143367A (enExample) |
| PL (1) | PL1656347T3 (enExample) |
| PT (1) | PT1656347E (enExample) |
| SA (1) | SA04250255B1 (enExample) |
| SE (1) | SE0302232D0 (enExample) |
| SI (1) | SI1656347T1 (enExample) |
| TW (1) | TW200510303A (enExample) |
| UY (1) | UY28473A1 (enExample) |
| WO (1) | WO2005019171A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| ES2304010T3 (es) | 2004-03-11 | 2008-09-01 | Actelion Pharmaceuticals Ltd. | Derivados de tetrahidropiridoindol. |
| CA2594280C (en) | 2004-12-27 | 2013-04-23 | Anja Fecher | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| JP5064219B2 (ja) | 2005-07-22 | 2012-10-31 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
| EP2397476A3 (en) | 2005-07-22 | 2011-12-28 | Shionogi & Co., Ltd. | Indole derivative having PGD2 receptor antagonist activity |
| GB0521275D0 (en) * | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| CN102558021A (zh) * | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
| WO2013142295A1 (en) | 2012-03-21 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
| EP3175856A1 (en) | 2006-06-16 | 2017-06-07 | The Trustees of the University of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss |
| US20150072963A1 (en) * | 2006-06-16 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
| WO2008012511A1 (en) | 2006-07-22 | 2008-01-31 | Oxagen Limited | Compounds having crth2 antagonist activity |
| MY147588A (en) | 2006-08-07 | 2012-12-31 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| EP2402314B1 (en) | 2007-04-11 | 2013-07-31 | Kissei Pharmaceutical Co., Ltd. | (Aza)indole derivative and use thereof for medical purposes |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| EP2229358B1 (en) | 2007-12-14 | 2011-03-23 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| CN101932571B (zh) | 2008-01-18 | 2014-04-23 | 奥克萨根有限公司 | 具有crth2拮抗活性的化合物 |
| US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
| EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8461329B2 (en) * | 2008-12-25 | 2013-06-11 | Taisho Pharmaceutical Co., Ltd. | Isoquinoline derivative |
| SG10201402346UA (en) * | 2009-05-19 | 2014-10-30 | Vivia Biotech Sl | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| WO2011004182A1 (en) * | 2009-07-06 | 2011-01-13 | Astrazeneca Ab | Intermediates and processes for the preparation of 4- (acetylamino) ) -3- [ (4-chloro-phenyl) thio] -2-methyl-1h-indole-1-acetic acid |
| KR20130029368A (ko) * | 2010-02-11 | 2013-03-22 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 피라졸로피리딘, 피라졸로피라진, 피라졸로피리미딘, 피라졸로티오펜 및 피라졸로티아졸 화합물, 조성물, 및 신경 기능이상을 치료하는 방법 |
| DK2558447T3 (da) | 2010-03-22 | 2014-11-10 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazolderivater og deres anvendelse som prostaglandin d2-receptormodulatorer |
| KR20130087399A (ko) | 2010-06-23 | 2013-08-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 이소퀴놀린 유도체 |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| KR101928595B1 (ko) | 2011-04-14 | 2018-12-12 | 이도르시아 파마슈티컬스 리미티드 | 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도 |
| EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| JP6152489B2 (ja) | 2014-03-17 | 2017-06-21 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| MX2016011900A (es) | 2014-03-18 | 2016-12-05 | Actelion Pharmaceuticals Ltd | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
| EP3256121B1 (en) | 2015-02-13 | 2024-08-07 | INSERM - Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| US12201625B2 (en) | 2015-07-30 | 2025-01-21 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 |
| CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
| KR102734880B1 (ko) * | 2020-10-28 | 2024-11-27 | 시오노기 앤드 컴파니, 리미티드 | 항바이러스 활성을 갖는 아마이드 유도체 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPH0615542B2 (ja) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
| WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
| FR2692574B1 (fr) | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
| HUT74614A (en) | 1993-02-24 | 1997-01-28 | Merck & Co Inc | Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them |
| US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| AR017256A1 (es) | 1997-08-21 | 2001-09-05 | American Home Prod | Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden |
| DK0924209T3 (da) | 1997-12-19 | 2003-08-25 | Lilly Co Eli | Hypoglykæmiske imidazolinforbindelser |
| US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| WO2000078761A1 (en) | 1999-06-23 | 2000-12-28 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
| AU7962200A (en) | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
| EP1990343B1 (en) | 1999-12-24 | 2012-04-04 | Aventis Pharma Limited | Azaindoles |
| CA2406979A1 (en) * | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| US6933316B2 (en) | 2001-12-13 | 2005-08-23 | National Health Research Institutes | Indole compounds |
| DK1501826T3 (da) | 2002-02-01 | 2007-01-29 | Hoffmann La Roche | Substituerede indoler som alpha-1-agonister |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| WO2003097598A1 (en) * | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) * | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| CN102558021A (zh) | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
| CA2654026A1 (en) | 2006-06-08 | 2007-12-13 | Neurokey A/S | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| WO2008000409A1 (en) | 2006-06-28 | 2008-01-03 | Sanofi-Aventis | New cxcr2 inhibitors |
-
2003
- 2003-08-18 SE SE0302232A patent/SE0302232D0/xx unknown
-
2004
- 2004-08-06 TW TW093123728A patent/TW200510303A/zh unknown
- 2004-08-16 PL PL04768065T patent/PL1656347T3/pl unknown
- 2004-08-16 ES ES04768065T patent/ES2352201T3/es not_active Expired - Lifetime
- 2004-08-16 US US10/568,889 patent/US7709521B2/en not_active Expired - Fee Related
- 2004-08-16 DE DE602004029580T patent/DE602004029580D1/de not_active Expired - Lifetime
- 2004-08-16 SI SI200431554T patent/SI1656347T1/sl unknown
- 2004-08-16 PT PT04768065T patent/PT1656347E/pt unknown
- 2004-08-16 WO PCT/GB2004/003502 patent/WO2005019171A1/en not_active Ceased
- 2004-08-16 EP EP04768065A patent/EP1656347B1/en not_active Expired - Lifetime
- 2004-08-16 SA SA04250255A patent/SA04250255B1/ar unknown
- 2004-08-16 MY MYPI20043328A patent/MY143367A/en unknown
- 2004-08-16 AT AT04768065T patent/ATE484494T1/de active
- 2004-08-16 DK DK04768065.7T patent/DK1656347T3/da active
- 2004-08-16 JP JP2006523677A patent/JP4709758B2/ja not_active Expired - Fee Related
- 2004-08-17 UY UY28473A patent/UY28473A1/es unknown
- 2004-08-18 AR ARP040102959A patent/AR045462A1/es not_active Application Discontinuation
-
2010
- 2010-12-09 CY CY20101101133T patent/CY1110977T1/el unknown